Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 202-212

  Kieffer, Tara L ^a   Kwong, Ann D ^a   Picchio, Gaston R ^b  

^a VERTEX PHARMACEUTICALS   (United States)

^b Tibotec Inc   (United States)

Author keywords

Mutations; Polymerase inhibitors; Protease inhibitors; Variants

Indexed keywords

5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ANTIVIRUS AGENT; BI 201335; BOCEPRAVIR; ITMN 191; N [[[6 (2 CARBOXY 2,3 DIHYDRO 1H ISOINDOL 4 YL) 2,2 DIMETHYLHEXYL]OXY]CARBONYL] 3 METHYLVALYL 4 HYDROXYPROLYL 1 AMINO N (CYCLOPROPYLSULFONYL) 2 ETHYLCYCLOPROPANECARBOXAMIDE LACTONE; PEGINTERFERON; PF 00868554; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPECIFICALLY TARGETED ANTIVIRAL THERAPIES FOR HEPATITIS C; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; VCH 916;

ANTIVIRAL SUSCEPTIBILITY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PATIENT COMPLIANCE; PHENOTYPE; POINT MUTATION; QUALITY OF LIFE; REVIEW; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 77950203857     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp388     Document Type: Review

References (78)

1. World Health Organization. Viral Cancers. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html (1 July 2009, date last accessed).
2. Ryder SD. Outcome of hepatitis C infection: bleak or benign? J Hepatol 2007; 47:4-6.
3. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
6. Bini EJ, Brau N, Currie S et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 1772-9.
7. Nainan OV, Alter MJ, Kruszon-Moran D et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-84.
8. Lamarre D, Anderson PC, Bailey M et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-9.
9. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
10. Kwo P, Lawitz EJ, McCone J et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 4, p. S4. Elsevier Science BV, Amsterdam, The Netherlands.
11. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
12. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis 2009; 48: 313-20.
13. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-7.
14. Ogata N, Alter HJ, Miller RH et al. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 3392-6.
15. Perelson AS. Will Interferon Always be Required for HCV Therapy? AASLD Hepatitis Single Topic Conference on Viral Hepatitis Therapy 2008. American Association for the Study of Liver Diseases. Available at: http://www.aasld.org/conferences/Documents/Past%20Conference% 20Syllabi/HepatitisSTC08.pdf (1 July 2009, date last accessed).
16. Manns MP, Bourliere M, Benhamou Y et al. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype-1 infection given as monotherapy and in combination with peginterferon alfa 2a (P) and ribavirin (R). In: Abstracts of the Fifty-ninth Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2008. Abstract 1849, p. 1133A. John Wiley & Sons Inc., Hoboken, NJ, USA.
17. Zeuzem S, Sarrazin C, Rouzier R et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-α). In: Abstracts of the Fifty-sixth Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2005. Abstract 94, p. 233A-4A. John Wiley & Sons Inc., Hoboken, NJ, USA.
18. Forestier N, Larrey DG, Guyader D et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. In: Abstracts of the Fifty-ninth Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2008. Abstract 1847, p. 1132A. John Wiley & Sons Inc., Hoboken, NJ, USA.
19. Sarrazin C, Hong J, Lim S et al. Incidence of virologic escape observed during ITMN-191 (R7227) monotherapy is genotype dependent, associated with a specific NS3 substitution, and suppressed upon combination with peginterferon alfa-2a/ribavirin. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 964, p. S350. Elsevier Science BV, Amsterdam, The Netherlands.
20. Lawitz EJ, Sulkowski MS, Jacobson IM et al. Safety, Tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection. In: Abstracts of the Fifty-ninth Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2008. Abstract 211, p. 403A. John Wiley & Sons Inc., Hoboken, NJ, USA.
21. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-77.
22. Villano S, Howe A, Raible D et al. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a nonnucleoside polymerase inhibitor, in treatment naïve HCV-infected patients. In: Abstracts of the Fifty-seventh Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, 2006. Abstract 1127, p. 607A. Elsevier Science BV, Amsterdam, The Netherlands.
23. Troke P, Lewis M, Simpson P et al. Genotypic characterisation of HCV NS5B following 8-day monotherapy with the polymerase inhibitor PF-00868554 in HCV-infected subjects. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 968, p. S351. Elsevier Science BV, Amsterdam, The Netherlands.
24. Nicolas O, Boivin I, Berneche-D'Amours A et al. Genotypic and phenotypic analysis of HCV NS5B variants selected from patients treated with VCH-916. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 961, p. S349. Elsevier Science BV, Amsterdam, The Netherlands.
25. Kukolj G, Benhamou Y, Manns MP et al. BI 201335, a potent HCV NS3 protease inhibitor in treatment naive and -experienced chronic HCV genotype infection: genotypic and phenotypic analysis of the NS3 protease domain. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 954, p. S347. Elsevier Science BV, Amsterdam, The Netherlands.
26. Kieffer TL, Sarrazin C, Miller JS et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-9.
27. Forestier N, Reesink HW, Weegink CJ et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640-8.
28. Curry S, Qiu P, Tong X. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods 2008; 153: 156-62.
29. Forestier N, Larrey DG, Guyader D et al. Antiviral activity and safety of ITMN-191 in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV). In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 85, p. S35. Elsevier Science BV, Amsterdam, The Netherlands.
30. Manns MP, Bourliere M, Benhamou Y et al. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa 2a (P) and ribavirin (R) for 28 days in P{thorn}R treatment-experienced patients with chronic hepatitis C genotype-1 infection. In: Abstracts of the Fifty-ninth Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2008. Abstract 1849, p. 1133A. John Wiley & Sons Inc., Hoboken, NJ, USA.
31. Bacheler LT. Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist Updat 1999; 2: 56-67.
32. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, 3 November 2008. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (1 July 2009, date last accessed).
33. Yi M, Tong X, Skelton A et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006; 281: 8205-15.
34. Tong X, Chase R, Skelton A et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70: 28-38.
35. Le Pogam S, Seshaadri A, Kosaka A et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008; 61: 1205-16.
36. Bartels DJ, Zhou Y, Zhang EZ et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198: 800-7.
37. Kuntzen T, Timm J, Berical A et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48: 1769-78.
38. Nijhuis M, van Maarseveen NM, Boucher CA. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol 2009; 189: 299-320.
39. Zhang EZ, Bartels D, Sullivan J et al. Cleavage sites during treatment with telaprevir, peg-IFN-alfa-2a, and ribavirin in phase II studies of treatment-naive HCV genotype 1-infected patients. In: Abstracts of the Fifty-ninth Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2008. Abstract 1856, p. 1138A. John Wiley & Sons Inc., Hoboken, NJ, USA.
40. Susser S, Welker MW, Zettler M et al. Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with boceprevir (SCH503034). In: Abstracts of the Forty-third Annual Meeting of the European Association for the Study of the Liver, Milan, 2008. Abstract 65, p. S29. Elsevier Science BV, Amsterdam, The Netherlands.
41. Susser S, Forestier N, Welker MW et al. Detection of resistant variants in the hepatitis C virus NS3 protease gene by clonal sequencing at long-term follow-up in patients treated with boceprevir. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 12, p. S7. Elsevier Science BV, Amsterdam, The Netherlands.
42. Forestier N, Susser S, Welker MW et al. Long term follow up of patients previously treated with telaprevir. In: Abstracts of the Fifty-ninth Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 2008. Abstract 1011, p. 760A. John Wiley & Sons Inc., Hoboken, NJ, USA.
43. Soriano V, Perelson AS, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother 2008; 62:1-4.
44. Pawlotsky JM. Virology of hepatitis B and C viruses and antiviral targets. J Hepatol 2006; 44: S10-3.
45. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54: 6-9.
46. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother 2005; 55: 413-6.
47. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
48. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
49. Turner BG, Summers MF. Structural biology of HIV. J Mol Biol 1999; 285: 1-32.
50. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
51. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-41.
52. Swain MG, Shiffman ML. Sustained virologic response (SVR) resulting from treatment with peginterferon alfa-2a (40KD) (Pegasys®) alone or in combination with ribavirin (Copegus®) is durable and constitutes a cure: an ongoing 5-year follow-up. In: Abstracts of Digestive Disease Week Meeting/ASGE Postgraduate Course Meeting, Washington, DC, 2007. Abstract 444, p. A741. WB Saunders Co.-Elsevier Inc., Philadelphia, PA, USA.
53. Qiu P, Sanfiorenzo V, Curry S et al. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 2009; 37: e74.
54. Ludmerer SW, Graham DJ, Boots E et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005; 49: 2059-69.
55. Zhou Y, Müh U, Hanzelka BL et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282: 22619-28.
56. Zhou Y, Bartels DJ, Hanzelka BL et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2008; 52: 110-20.
57. Kwong AD, McNair L, Jacobson I et al. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol 2008; 8: 522-31.
58. McCown MF, Rajyaguru S, Kular S et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53: 2129-32.
59. Tong X, Bogen S, Chase R et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77: 177-85.
60. Le Pogam S, Seshaadri A, Kang H et al. Low level of resistance, low viral fitness and absence of resistance mutations in baseline quasispecies may contribute to high barrier to R1626 resistance in vivo. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 21, p. S10. Elsevier Science BV, Amsterdam, The Netherlands.
61. Cretton-Scott E, Perigaud C, Peyrottes S et al. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. In: Abstracts of the Forty-third Annual Meeting of the European Association for the Study of the Liver, Milan, 2008. Abstract 588, p. S220. Elsevier Science BV, Amsterdam, The Netherlands.
62. Koev G, Mondal R, Beyer J et al. Characterization of resistance mutations selected in vitro by the non-nucleoside HCV polymerase inhibitors ABT-333 and ABT-072. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 953, p. S346. Elsevier Science BV, Amsterdam, The Netherlands.
63. Le Pogam S, Seshaadri A, Kosaka A et al. No evidence of R7128 drug resistance after up to 4 weeks treatment of GT 1, 2 and 3 hepatitis C virus infected individuals. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 958, p. S348. Elsevier Science BV, Amsterdam, The Netherlands.
64. Manns M, Reesink H, Moreno C et al. OPERA-1 trial: interim analysis of safety and antiviral activity of TMC435 in treatment-naïve genotype 1 HCV patients. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 11, p. S7. Elsevier Science BV, Amsterdam, The Netherlands.
65. Manns MP, Gane E, Rodriguez-Torres M et al. MK-7009 significantly improves rapid viral response (RVR) in combination with pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C (CHC) genotype 1 infection. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 1056, p. S384. Elsevier Science BV, Amsterdam, The Netherlands.
66. Shi ST, Herlihy KJ, Graham JP et al. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009; 53: 2544-52.
67. Cornberg M, Manns MP, Wedemeyer H. Standard of care. In: Mauss S, Berg T, Rockstroh J et al., eds. Hepatology: A Clinical Textbook. Flying Publisher, 2009; 183-210.
68. Manns M, Muir A, Adda N et al. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy: SVR results of the PROVE3 study. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 1044, p. S379. Elsevier Science BV, Amsterdam, The Netherlands.
69. McHutchison JG, Everson GT, Jacobson IM et al. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. In: Abstracts of the Forty-third Annual Meeting of the European Association for the Study of the Liver, Milan, 2008. Abstract 4, p. S4. Elsevier Science BV, Amsterdam, The Netherlands.
70. Kwo P, Lawitz EJ, McCone J et al. HCV SPRINT-1: boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. In: Abstracts of the Fifty-ninth Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA, 2008. Abstract LB15, p. 1027A. Elsevier Science BV, Amsterdam, The Netherlands.
71. Shiffman ML, Mansbach H, Hammond J et al. The effect of complete and partial response at week 12 on sustained virologic response: results from controlled trials in naïve HCV genotype 1 patients treated with pegylated interferon and ribavirin. In: Abstracts of the Fifty-eighth Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2007. Abstract 1320, p. 824A. John Wiley & Sons Inc., Hoboken, NJ, USA.
72. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
73. Rockstroh JK, Bhagani S, Benhamou Y et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-8.
74. Kieffer T, Sarrazin C, Bartels D et al. Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV. In: Abstracts of the Forty-first Annual Meeting of the European Association for the Study of Liver, Vienna, 2006. Abstract 12, p. S7. Elsevier Science BV, Amsterdam, The Netherlands.
75. Sarrazin C, Rouzier R, Wagner F et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270-8.
76. Lin C, Lin K, Luong YP et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 17508-14.
77. Kempf DJ, Klein C, Chen HJ et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007; 18: 163-7.
78. Gane EJ, Roberts SK, Stedman C et al. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. In: Abstracts of the Forty-fourth Annual Meeting of the European Association for the Study of the Liver, Copenhagen, 2009. Abstract 1046, p. S380. Elsevier Science BV, Amsterdam, The Netherlands.